Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Internal Medicine
- Dapagliflozin in Patients with Chronic Kidney Disease.N Engl J Med. 2020;
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.N Engl J Med. 2020;
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.N Engl J Med. 2020;
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.N Engl J Med. 2019; 381: 1995-2008
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.N Engl J Med. 2019; 380: 2295-2306
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.N Engl J Med. 2019; 380: 347-357
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.N Engl J Med. 2017; 377: 644-657
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.N Engl J Med. 2015; 373: 2117-2128
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.Lancet. 2019; 393: 31-39
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.Lancet. 2020;